Influenced factor for outcome of H. pylori eradication therapy: retrospective study

Influenced factor for outcome of H. pylori eradication therapy: retrospective study - Association with H. pylori eradication and CYP3A4/5 type

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024172

Enrollment

150

Registered

2016-10-01

Start date

2016-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H. pylori infection associated gastritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients eradicated H. pylori form April 2013 to July 2016 in Shiga University of Medical Science Hospital. 2. patients received informed consent previously for genotyping of CYP2C19 and drug-metabolized enzyme genes.

Exclusion criteria

Exclusion criteria: 1. Without informed consent 2. without detail clinical data, such as kinds of eradication regimen, age, sex, side effects, outcome of eradication therapy, severity of gastric mucosal atrophy, status of GERD, peptic ulcer and gastric cancer, smoking, alcohol, and CYP2C19 genotype status.

Design outcomes

Primary

Measure	Time frame
Eradication rate of H. pylori infection	—

Secondary

Measure	Time frame
(1) incidence rate of adverse effects (2) influence of CYP2C19 genotypes for outcome of eradication therapy (3) influence of CYP3A4/5 genotypes for outcome of eradication therapy (4) influence of susceptibility to antimicrobial agents for outcome of eradication therapy	—

Countries

Japan

Contacts

Public ContactMitsushige Sugimoto

Shiga University of Medical Science Hospital Division of Digestive Endoscopy

sugimo@belle.shiga-med.ac.jp077-548-2618

Outcome results